Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone‐sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study. (6th May 2021)

• Record Type: Journal Article
• Authors: Iguchi, Taro; Kimura, Go; Fukasawa, Satoshi; Suzuki, Hiroyoshi; Uemura, Hiroji; Nishimura, Kazuo; Matsumoto, Hiroaki; Yokomizo, Akira; Armstrong, Andrew J; Rosbrook, Brad; Sugg, Jennifer; Baron, Benoit; Chen, Lucy; Kunieda, Futoshi; Stenzl, Arnulf
• Is Part Of: International journal of urology. Volume 28:Number 7(2021)
• Page Start: 765
• Page End: 773
• Publication Date: 2021-05-06
• Subjects: androgen receptor antagonists -- enzalutamide -- Japan -- metastatic prostate cancer; Urology -- Periodicals; Genitourinary organs -- Periodicals; Urologic Diseases -- Periodicals; 616.6005
• DOI: 10.1111/iju.14568
• Languages: English
• ISSNs: 0919-8172

Abstract

Abstract : Objective: To evaluate the efficacy and safety of enzalutamide plus androgen deprivation therapy in Japanese men with metastatic hormone‐sensitive prostate cancer. Methods: A post‐hoc analysis of the Japanese subgroup in the phase III, randomized, multinational ARCHES study (NCT02677896) was carried out. Patients with metastatic hormone‐sensitive prostate cancer were randomized to receive enzalutamide or a placebo, plus androgen deprivation therapy, stratified by disease volume and prior docetaxel therapy. The primary end‐point was radiographic progression‐free survival. Secondary end‐points included time to prostate‐specific antigen progression and overall survival. Results: Of 1150 patients, 92 Japanese patients were randomized to enzalutamide ( n = 36) or a placebo ( n = 56), plus androgen deprivation therapy; none received prior docetaxel. Enzalutamide plus androgen deprivation therapy reduced the risk of radiographic progression or death in Japanese patients by 61% versus the placebo, similar to the overall population. Similar results were observed with secondary end‐points, showing clinical benefit of enzalutamide plus androgen deprivation therapy in Japanese patients. Overall survival data were immature. Grade 3–4 adverse events were reported in 47% and 25% of the enzalutamide and placebo groups, respectively. Nasopharyngitis, hypertension and abnormal hepatic function were reported more frequently in Japanese patients versus the overall population. Conclusions: Enzalutamide plus androgen deprivation therapy has clinical benefit with a tolerable safety profile in Japanese men with metastatic hormone‐sensitive prostate cancer, consistent with the overall population.